查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1980061

更年期支持市场预测至2034年：按支持类型、症状类型、给药途径、剂型、最终用户、分销管道和地区分類的全球分析

Menopause Support Market Forecasts to 2034 - Global Analysis By Support Type, Symptom Type, Route of Administration, Dosage Form, End User, Distribution Channel, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的研究，预计到 2026 年，全球更年期支持市场将达到 183 亿美元，并在预测期内以 7.2% 的复合年增长率增长，到 2034 年达到 320 亿美元。

更年期支持产品包括药物、膳食补充剂和治疗性给药系统，旨在缓解闭经和更年期相关症状，例如潮热、情绪波动和阴道萎缩。该市场透过多种给药途径和剂型满足老年女性日益增长的健康需求。人们对更年期管理的认识不断提高，以及围绕这一人生阶段的讨论不再那么令人羞耻，正在推动产品创新，并扩大全球医疗保健系统中治疗的可及性。

全球老年女性人口数量增加

人口结构的变化导致全球45-60岁女性人口显着增长，从而扩大了更年期支持解决方案的潜在市场。随着预期寿命的延长，女性如今约有三分之一的人生处于停经后阶段，因此人们更加关注这段时期的生活品质。医疗保健系统也日益认识到，更年期并非不可避免的老化过程，而是需要全面管理的医学问题。这种人口结构的变化，加上成熟消费者可支配收入的增加，正在催生对能够缓解症状和维护长期健康的药物和天然支持产品的持续需求。

社会歧视和症状报告不足

围绕更年期的文化禁忌持续阻碍女性与医疗专业人员之间的公开对话，并限制市场成长。许多女性默默忍受更年期症状，要么不了解可用的治疗方法，要么因为羞于启齿而犹豫寻求医疗帮助。这种沟通障碍导致诊断不足和治疗不足的情况严重，尤其是在老化和女性健康问题仍然敏感的地区。更年期管理通常在医疗专业人员的培训中得到充分解释，这进一步加剧了治疗率低下的问题。克服这些文化障碍需要持续进行针对全球不同市场消费者和医疗专业人员的宣传活动。

个人化医疗与数位健康的融合

基因检测和生物标记分析技术的进步使得基于个别症状特征和健康史的个人化更年期治疗方案成为可能。提供症状追踪、远端医疗咨询和个人化营养补充剂推荐的数位健康平台，为寻求客製化解决方案的消费者开闢了新的互动管道。穿戴式装置监测睡眠模式、皮肤温度和心率变异性，为优化治疗方案提供客观数据。个人化医疗与数位工具的整合，使企业能够与消费者建立直接联繫，收集产品有效性的真实世界数据，并创建订阅模式，确保在首次产品购买后仍能与客户保持持续互动。

监管机构正在加强对生物同源激素的监管。

随着监管机构对复方生物同源荷尔蒙疗法的关注度不断提高，一个深受寻求「天然」替代疗法的消费者青睐的关键市场领域正面临威胁。卫生部门已对复方製剂的效力不稳定、缺乏标准化剂量以及安全性数据不足表示担忧。生产设施面临更严格的检测要求，而关于其疗效与FDA核准治疗方法的比较的营销声明也受到更严格的限制。限制复方荷尔蒙供应的监管措施可能会扰乱供应链和消费者获取途径，从而可能迫使患者转向传统药物治疗。然而，这可能造成市场不确定性，进而影响整个更年期支持产品领域的研发投资。

新冠疫情的影响：

新冠疫情透过降低医疗服务可近性和改变人们的健康优先事项，对更年期支持市场动态产生了影响。封锁措施限制了常规妇科就诊，并延误了新诊断和治疗的启动。远端医疗的普及在一定程度上缓解了这些干扰，导致更年期管理线上咨询量显着增加。疫情期间的压力和生活方式的改变加剧了许多女性的更年期症状，增加了潜在需求。供应链中断影响了某些产品的供应，尤其是需要低温运输储存的产品。在疫情后的恢復阶段，远端医疗在更年期照护的应用仍在持续，消费者对自我管理健康解决方案的兴趣也日益浓厚。

在预测期内，口服剂型预计将占据最大的市场份额。

预计在预测期内，口服剂型将占据最大的市场份额，这主要得益于患者对其剂型的熟悉度、给药便利性以及丰富的产品选择。片剂和胶囊是荷尔蒙疗法、营养补充剂和更年期症状草药疗法的传统剂型。口服製剂具有成熟的生产工艺，可确保剂量精准、保质期稳定且品质始终如一。消费者偏好便利、便携的日常用药方式，因此口服给药优于侵入性较强的给药途径。製药公司正不断研发新型口服给药技术，以提高生物利用度并减少胃肠道副作用。

在预测期内，补丁细分市场预计将呈现最高的复合年增长率。

在预测期内，贴片市场预计将呈现最高的成长率。其主要特征包括经经皮吸收持续释放激素，避免首过效应。贴片能稳定缓解症状，避免口服药物剂量波动带来的不便，因此深受寻求疗效可预测的女性欢迎。每週一次的用药方案也十分便捷，无需每日服药。越来越多的临床证据表明，与口服药物相比，经皮雌激素在心血管和血栓栓塞风险方面更具安全性，这促使医生更建议使用贴片。产品创新包括更小巧、更隐密、黏着性更强、皮肤刺激性更低的贴剂，从而提高了不同患者群体的接受度和依从性。

市占率最大的地区：

在预测期内，北美预计将保持最大的市场份额，这得益于较高的医疗保健意识、完善的医药基础设施以及对女性健康的积极态度。广泛的消费者广告提高了女性对治疗方案的了解，而全面的保险覆盖则改善了她们获得治疗的机会。主要市场公司在全部区域设有总部和生产设施，确保了稳定的产品供应。强大的临床研究基础设施产生了大量的安全性和有效性数据，为医生的处方决策提供支援。专业医学协会积极发布更年期管理指南，促进治疗方法和适当治疗性介入的标准化。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要受人口快速老化、医疗保健支出增加以及社会观念转变的驱动。日本、中国和韩国等国家正经历显着的人口结构变化，包括更年期女性人口的成长。可支配收入的增加使得人们更容易获得高品质的药品和保健产品。传统医学体系中融入的草药疗法正在促进人们对更年期辅助产品的自然接受。西方製药公司正透过与当地经销商建立策略合作伙伴关係，日益瞄准这些市场。医疗保健教育措施正在提升医疗服务提供者的知识水平，而媒体讨论也逐渐消除围绕更年期的文化偏见。

免费客製化服务：

购买此报告的客户可以选择以下免费自订选项之一：

  • 企业概况
    • 对其他市场公司（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域划分
    • 主要国家的市场估算和预测，以及根据客户需求量身定制的复合年增长率（註：需要进行可行性测试）。
  • 竞争性标竿分析
    • 根据主要企业的产品系列、地理覆盖范围和策略联盟进行基准分析。

目录

第一章执行摘要

  • 市场概览及主要亮点
  • 驱动因素、挑战与机会
  • 竞争格局概述
  • 战略洞察与建议

第二章：研究框架

  • 研究目标和范围
  • 相关人员分析
  • 研究假设和限制
  • 调查方法

第三章 市场动态与趋势分析

  • 市场定义与结构
  • 主要市场驱动因素
  • 市场限制与挑战
  • 投资成长机会和重点领域
  • 产业威胁与风险评估
  • 技术与创新展望
  • 新兴市场/高成长市场
  • 监管和政策环境
  • 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的竞争
  • 主要企业市占率分析
  • 产品基准评效和效能比较

第五章：全球更年期支持市场：依支持类型划分

  • 荷尔蒙疗法
    • 雌激素疗法
    • 联合荷尔蒙疗法
    • 黄体素疗法
  • 非荷尔蒙疗法
    • 处方笺非荷尔蒙药物
    • 非处方非荷尔蒙产品
  • 营养补充品
    • 草药补充剂
    • 维生素和矿物质
    • 植物雌激素
    • 欧米伽脂肪酸
    • 益生菌
    • 复合补充剂
  • 生活方式和健康解决方案
    • 健身和体重管理
    • 营养计划
    • 心理健康和压力管理
    • 睡眠支持解决方案
  • 医疗设备和数位疗法
    • 骨盆底健康设备
    • 穿戴式健康监测
    • 女性科技平台
    • 远端医疗和数位护理平台

第六章：全球更年期支持市场：依症状类型划分

  • 血管舒缩症状
  • 睡眠障碍
  • 情绪和认知症状
  • 阴道和泌尿生殖系统症状
  • 骨骼健康与骨质疏鬆症
  • 代谢和心血管问题
  • 性功能和性慾
  • 其他症状

第七章：全球更年期支持市场：依给药途径划分

  • 口服
  • 局部和经皮吸收
  • 注射药物
  • 阴道内给药系统

第八章：全球更年期支持市场：以剂型划分

  • 片剂和胶囊
  • 软凝胶
  • 粉末
  • 液体和滋补品
  • 修补
  • 乳霜和凝胶
  • 环和植入

第九章：全球更年期支持市场：依最终用户划分

  • 医院
  • 专科诊所
  • 诊断中心
  • 居家医疗环境
  • 健康中心及妇科诊所

第十章 全球更年期支援市场：依通路划分

  • 医院和诊所
  • 零售药局和药房
  • 网路药局和电子商务
  • 专卖店
  • 面向消费者的直销平台

第十一章 全球更年期支持市场：按地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十二章 策略市场资讯

  • 工业价值网络和供应链评估
  • 空白区域和机会地图
  • 产品演进与市场生命週期分析
  • 通路、经销商和打入市场策略的评估

第十三章 产业趋势与策略倡议

  • 併购
  • 伙伴关係、联盟和合资企业
  • 新产品发布和认证
  • 扩大生产能力和投资
  • 其他策略倡议

第十四章：公司简介

  • Bayer AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Theramex
  • Astellas Pharma Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Amgen Inc.
  • Merck & Co., Inc.
  • GSK plc
  • Nature's Way Products, LLC
  • Holland & Barrett Retail Limited
  • Bonafide Health, LLC
  • Metagenics, Inc.
  • Blackmores Limited
Product Code: SMRC34225

According to Stratistics MRC, the Global Menopause Support Market is accounted for $18.3 billion in 2026 and is expected to reach $32.0 billion by 2034 growing at a CAGR of 7.2% during the forecast period. Menopause support products encompass pharmaceutical treatments, dietary supplements, and therapeutic delivery systems designed to alleviate symptoms associated with perimenopause and menopause, including hot flashes, mood disturbances, and vaginal atrophy. The market addresses the health needs of the growing aging female population through diverse administration routes and dosage formats. Increasing awareness about menopause management and declining stigma around discussing this life stage are driving product innovation and expanding treatment accessibility across global healthcare systems.

Market Dynamics:

Driver:

Growing aging female population worldwide

Demographic trends show a significant increase in women aged 45-60 globally, creating an expanding addressable market for menopause support solutions. Longer life expectancy means women spend approximately one-third of their lives in post-menopausal phases, intensifying focus on quality of life during these years. Healthcare systems increasingly recognize menopause as a medical concern requiring comprehensive management rather than an inevitable decline. This demographic shift, combined with rising disposable incomes among mature consumers, generates sustained demand for both pharmaceutical interventions and natural support products addressing symptom management and long-term health preservation.

Restraint:

Social stigma and underreporting of symptoms

Cultural taboos surrounding menopause continue to limit market expansion by discouraging open discussions between women and healthcare providers. Many women endure symptoms silently, unaware of available treatment options or reluctant to seek medical assistance due to embarrassment. This communication gap results in significant underdiagnosis and undertreatment, particularly in regions where aging and female health topics remain sensitive. Healthcare provider training often inadequately addresses menopause management, further contributing to low treatment rates. Breaking these cultural barriers requires sustained educational efforts targeting both consumers and medical professionals across diverse global markets.

Opportunity:

Personalized medicine and digital health integration

Advances in genetic testing and biomarker analysis enable tailored menopause treatment approaches based on individual symptom profiles and health histories. Digital health platforms offering symptom tracking, telehealth consultations, and personalized supplement recommendations create new engagement channels with consumers seeking customized solutions. Wearable devices monitoring sleep patterns, skin temperature, and heart rate variability provide objective data for treatment optimization. This convergence of personalized medicine and digital tools allows companies to develop direct-to-consumer relationships, gather real-world evidence on product efficacy, and create subscription-based models ensuring ongoing customer engagement beyond initial product purchase.

Threat:

Regulatory scrutiny of bioidentical hormones

Increasing regulatory attention on compounded bioidentical hormone therapies threatens a significant market segment favored by consumers seeking "natural" alternatives. Health authorities express concerns about inconsistent potency, lack of standardized dosing, and insufficient safety data for custom-compounded preparations. Manufacturing facilities face intensified inspection requirements, while marketing claims face greater restrictions regarding efficacy comparisons to FDA-approved therapies. Regulatory actions limiting compounded hormone availability could disrupt supply chains and consumer access, potentially driving patients toward conventional pharmaceutical options but creating market uncertainty that impacts investment in product development across the menopause support category.

Covid-19 Impact:

The COVID-19 pandemic disrupted menopause support market dynamics through reduced healthcare access and shifting health priorities. Lockdowns limited routine gynecological visits, delaying new diagnoses and treatment initiations. Telehealth adoption partially offset these disruptions, with virtual consultations for menopause management increasing significantly. Stress and lifestyle changes during pandemic periods exacerbated menopausal symptoms for many women, increasing underlying demand. Supply chain interruptions affected availability of specific products, particularly those requiring cold chain storage. Post-pandemic recovery shows sustained telehealth utilization for menopause care and heightened consumer interest in self-managed wellness solutions.

The Oral segment is expected to be the largest during the forecast period

The Oral segment is expected to account for the largest market share during the forecast period, driven by patient familiarity, ease of administration, and extensive product availability. Tablets and capsules represent conventional dosage forms for hormone therapies, dietary supplements, and herbal remedies addressing menopausal symptoms. Oral formulations offer precise dosing, stable shelf lives, and established manufacturing processes ensuring consistent quality. Consumer preference for discrete, portable, and simple daily routines favors oral administration over more invasive alternatives. Pharmaceutical companies continue developing novel oral delivery technologies improving bioavailability and reducing gastrointestinal side effects.

The Patches segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Patches segment is predicted to witness the highest growth rate, offering consistent hormone delivery through transdermal absorption while avoiding first-pass liver metabolism. Patches provide steady symptom relief without oral medication fluctuations, appealing to women seeking predictable outcomes. Convenience factors include once-weekly application schedules eliminating daily dosing requirements. Growing clinical evidence supporting transdermal estrogen safety regarding cardiovascular and thromboembolic risks compared to oral alternatives drives physician recommendations. Product innovations include smaller, more discreet patches with improved adhesion and reduced skin irritation, expanding patient acceptance and compliance across diverse demographics.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by high healthcare awareness, strong pharmaceutical infrastructure, and progressive attitudes toward women's health. Extensive direct-to-consumer advertising educates women about treatment options, while robust insurance coverage improves treatment accessibility. Major market players maintain headquarters and manufacturing facilities throughout the region, ensuring consistent product availability. Clinical research infrastructure generates extensive safety and efficacy data supporting physician prescribing confidence. Professional medical societies actively publish menopause management guidelines, standardizing treatment approaches and encouraging appropriate therapeutic interventions.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by rapidly aging populations, increasing healthcare expenditure, and evolving social attitudes. Countries including Japan, China, and South Korea experience significant demographic shifts with growing cohorts of menopausal women. Rising disposable incomes enable access to premium pharmaceutical and wellness products. Traditional medicine systems incorporating herbal approaches to menopause create natural acceptance of support products. Western pharmaceutical companies increasingly target these markets through strategic partnerships with local distributors. Medical education initiatives improve healthcare provider knowledge, while media discussions gradually reduce cultural stigma surrounding menopause.

Key players in the market

Some of the key players in Menopause Support Market include Bayer AG, Pfizer Inc., AbbVie Inc., Theramex, Astellas Pharma Inc., Eli Lilly and Company, Novartis AG, Amgen Inc., Merck & Co., Inc., GSK plc, Nature's Way Products, LLC, Holland & Barrett Retail Limited, Bonafide Health, LLC, Metagenics, Inc., and Blackmores Limited.

Key Developments:

In February 2026, Bayer presented new real-world evidence from the CHAPTER and REALISE studies at the Menopause Society Annual Meeting, highlighting significant undertreatment in natural menopause and the high use of benzodiazepines for sleep disturbances.

In February 2026, Astellas announced that its non-hormonal drug Veozah (fezolinetant) met its primary endpoint in a Japanese Phase III study, paving the way for regulatory submission and market entry in Japan.

In October 2025, Bonafide released its "State of Menopause" report, revealing that 59% of women aged 40-49 had never heard of perimenopause before experiencing symptoms, driving the company's 2026 strategy toward hormone-free education and clinical-grade supplements.

Support Types Covered:

  • Hormonal Therapies
  • Non-Hormonal Therapies
  • Dietary Supplements
  • Lifestyle and Wellness Solutions
  • Medical Devices and Digital Therapeutics

Symptom Types Covered:

  • Vasomotor Symptoms
  • Sleep Disorders
  • Mood and Cognitive Symptoms
  • Vaginal and Urogenital Symptoms
  • Bone Health and Osteoporosis
  • Metabolic and Cardiovascular Concerns
  • Sexual Health and Libido
  • Other Symptoms

Route of Administrations Covered:

  • Oral
  • Topical and Transdermal
  • Injectable
  • Vaginal Delivery Systems

Dosage Forms Covered:

  • Tablets and Capsules
  • Softgels
  • Powders
  • Liquids and Tonics
  • Patches
  • Creams and Gels
  • Rings and Implants

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Homecare Settings
  • Wellness Centers and Gynecology Clinics

Distribution Channels Covered:

  • Hospitals and Clinics
  • Retail Pharmacies and Drug Stores
  • Online Pharmacies and E-commerce
  • Specialty Stores
  • Direct-to-Consumer Platforms

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Menopause Support Market, By Support Type

  • 5.1 Hormonal Therapies
    • 5.1.1 Estrogen Therapy
    • 5.1.2 Combined Hormone Therapy
    • 5.1.3 Progesterone Therapy
  • 5.2 Non-Hormonal Therapies
    • 5.2.1 Prescription Non-Hormonal Drugs
    • 5.2.2 OTC Non-Hormonal Products
  • 5.3 Dietary Supplements
    • 5.3.1 Herbal Supplements
    • 5.3.2 Vitamins and Minerals
    • 5.3.3 Phytoestrogens
    • 5.3.4 Omega Fatty Acids
    • 5.3.5 Probiotics
    • 5.3.6 Combination Supplements
  • 5.4 Lifestyle and Wellness Solutions
    • 5.4.1 Fitness and Weight Management
    • 5.4.2 Nutrition Programs
    • 5.4.3 Mental Health and Stress Management
    • 5.4.4 Sleep Support Solutions
  • 5.5 Medical Devices and Digital Therapeutics
    • 5.5.1 Pelvic Health Devices
    • 5.5.2 Wearable Health Monitoring
    • 5.5.3 Femtech Platforms
    • 5.5.4 Telehealth and Digital Care Platforms

6 Global Menopause Support Market, By Symptom Type

  • 6.1 Vasomotor Symptoms
  • 6.2 Sleep Disorders
  • 6.3 Mood and Cognitive Symptoms
  • 6.4 Vaginal and Urogenital Symptoms
  • 6.5 Bone Health and Osteoporosis
  • 6.6 Metabolic and Cardiovascular Concerns
  • 6.7 Sexual Health and Libido
  • 6.8 Other Symptoms

7 Global Menopause Support Market, By Route of Administration

  • 7.1 Oral
  • 7.2 Topical and Transdermal
  • 7.3 Injectable
  • 7.4 Vaginal Delivery Systems

8 Global Menopause Support Market, By Dosage Form

  • 8.1 Tablets and Capsules
  • 8.2 Softgels
  • 8.3 Powders
  • 8.4 Liquids and Tonics
  • 8.5 Patches
  • 8.6 Creams and Gels
  • 8.7 Rings and Implants

9 Global Menopause Support Market, By End User

  • 9.1 Hospitals
  • 9.2 Specialty Clinics
  • 9.3 Diagnostic Centers
  • 9.4 Homecare Settings
  • 9.5 Wellness Centers and Gynecology Clinics

10 Global Menopause Support Market, By Distribution Channel

  • 10.1 Hospitals and Clinics
  • 10.2 Retail Pharmacies and Drug Stores
  • 10.3 Online Pharmacies and E-commerce
  • 10.4 Specialty Stores
  • 10.5 Direct-to-Consumer Platforms

11 Global Menopause Support Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Bayer AG
  • 14.2 Pfizer Inc.
  • 14.3 AbbVie Inc.
  • 14.4 Theramex
  • 14.5 Astellas Pharma Inc.
  • 14.6 Eli Lilly and Company
  • 14.7 Novartis AG
  • 14.8 Amgen Inc.
  • 14.9 Merck & Co., Inc.
  • 14.10 GSK plc
  • 14.11 Nature's Way Products, LLC
  • 14.12 Holland & Barrett Retail Limited
  • 14.13 Bonafide Health, LLC
  • 14.14 Metagenics, Inc.
  • 14.15 Blackmores Limited

List of Tables

  • Table 1 Global Menopause Support Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Menopause Support Market Outlook, By Support Type (2023-2034) ($MN)
  • Table 3 Global Menopause Support Market Outlook, By Hormonal Therapies (2023-2034) ($MN)
  • Table 4 Global Menopause Support Market Outlook, By Estrogen Therapy (2023-2034) ($MN)
  • Table 5 Global Menopause Support Market Outlook, By Combined Hormone Therapy (2023-2034) ($MN)
  • Table 6 Global Menopause Support Market Outlook, By Progesterone Therapy (2023-2034) ($MN)
  • Table 7 Global Menopause Support Market Outlook, By Non-Hormonal Therapies (2023-2034) ($MN)
  • Table 8 Global Menopause Support Market Outlook, By Prescription Non-Hormonal Drugs (2023-2034) ($MN)
  • Table 9 Global Menopause Support Market Outlook, By OTC Non-Hormonal Products (2023-2034) ($MN)
  • Table 10 Global Menopause Support Market Outlook, By Dietary Supplements (2023-2034) ($MN)
  • Table 11 Global Menopause Support Market Outlook, By Herbal Supplements (2023-2034) ($MN)
  • Table 12 Global Menopause Support Market Outlook, By Vitamins and Minerals (2023-2034) ($MN)
  • Table 13 Global Menopause Support Market Outlook, By Phytoestrogens (2023-2034) ($MN)
  • Table 14 Global Menopause Support Market Outlook, By Omega Fatty Acids (2023-2034) ($MN)
  • Table 15 Global Menopause Support Market Outlook, By Probiotics (2023-2034) ($MN)
  • Table 16 Global Menopause Support Market Outlook, By Combination Supplements (2023-2034) ($MN)
  • Table 17 Global Menopause Support Market Outlook, By Lifestyle and Wellness Solutions (2023-2034) ($MN)
  • Table 18 Global Menopause Support Market Outlook, By Fitness and Weight Management (2023-2034) ($MN)
  • Table 19 Global Menopause Support Market Outlook, By Nutrition Programs (2023-2034) ($MN)
  • Table 20 Global Menopause Support Market Outlook, By Mental Health and Stress Management (2023-2034) ($MN)
  • Table 21 Global Menopause Support Market Outlook, By Sleep Support Solutions (2023-2034) ($MN)
  • Table 22 Global Menopause Support Market Outlook, By Medical Devices and Digital Therapeutics (2023-2034) ($MN)
  • Table 23 Global Menopause Support Market Outlook, By Pelvic Health Devices (2023-2034) ($MN)
  • Table 24 Global Menopause Support Market Outlook, By Wearable Health Monitoring (2023-2034) ($MN)
  • Table 25 Global Menopause Support Market Outlook, By Femtech Platforms (2023-2034) ($MN)
  • Table 26 Global Menopause Support Market Outlook, By Telehealth and Digital Care Platforms (2023-2034) ($MN)
  • Table 27 Global Menopause Support Market Outlook, By Symptom Type (2023-2034) ($MN)
  • Table 28 Global Menopause Support Market Outlook, By Vasomotor Symptoms (2023-2034) ($MN)
  • Table 29 Global Menopause Support Market Outlook, By Sleep Disorders (2023-2034) ($MN)
  • Table 30 Global Menopause Support Market Outlook, By Mood and Cognitive Symptoms (2023-2034) ($MN)
  • Table 31 Global Menopause Support Market Outlook, By Vaginal and Urogenital Symptoms (2023-2034) ($MN)
  • Table 32 Global Menopause Support Market Outlook, By Bone Health and Osteoporosis (2023-2034) ($MN)
  • Table 33 Global Menopause Support Market Outlook, By Metabolic and Cardiovascular Concerns (2023-2034) ($MN)
  • Table 34 Global Menopause Support Market Outlook, By Sexual Health and Libido (2023-2034) ($MN)
  • Table 35 Global Menopause Support Market Outlook, By Other Symptoms (2023-2034) ($MN)
  • Table 36 Global Menopause Support Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 37 Global Menopause Support Market Outlook, By Oral (2023-2034) ($MN)
  • Table 38 Global Menopause Support Market Outlook, By Topical and Transdermal (2023-2034) ($MN)
  • Table 39 Global Menopause Support Market Outlook, By Injectable (2023-2034) ($MN)
  • Table 40 Global Menopause Support Market Outlook, By Vaginal Delivery Systems (2023-2034) ($MN)
  • Table 41 Global Menopause Support Market Outlook, By Dosage Form (2023-2034) ($MN)
  • Table 42 Global Menopause Support Market Outlook, By Tablets and Capsules (2023-2034) ($MN)
  • Table 43 Global Menopause Support Market Outlook, By Softgels (2023-2034) ($MN)
  • Table 44 Global Menopause Support Market Outlook, By Powders (2023-2034) ($MN)
  • Table 45 Global Menopause Support Market Outlook, By Liquids and Tonics (2023-2034) ($MN)
  • Table 46 Global Menopause Support Market Outlook, By Patches (2023-2034) ($MN)
  • Table 47 Global Menopause Support Market Outlook, By Creams and Gels (2023-2034) ($MN)
  • Table 48 Global Menopause Support Market Outlook, By Rings and Implants (2023-2034) ($MN)
  • Table 49 Global Menopause Support Market Outlook, By End User (2023-2034) ($MN)
  • Table 50 Global Menopause Support Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 51 Global Menopause Support Market Outlook, By Specialty Clinics (2023-2034) ($MN)
  • Table 52 Global Menopause Support Market Outlook, By Diagnostic Centers (2023-2034) ($MN)
  • Table 53 Global Menopause Support Market Outlook, By Homecare Settings (2023-2034) ($MN)
  • Table 54 Global Menopause Support Market Outlook, By Wellness Centers and Gynecology Clinics (2023-2034) ($MN)
  • Table 55 Global Menopause Support Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 56 Global Menopause Support Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
  • Table 57 Global Menopause Support Market Outlook, By Retail Pharmacies and Drug Stores (2023-2034) ($MN)
  • Table 58 Global Menopause Support Market Outlook, By Online Pharmacies and E-commerce (2023-2034) ($MN)
  • Table 59 Global Menopause Support Market Outlook, By Specialty Stores (2023-2034) ($MN)
  • Table 60 Global Menopause Support Market Outlook, By Direct-to-Consumer Platforms (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.